[vc_row][vc_column][vc_column_text]The RESIST project, in which GAIKER participates, will develop new drugs based on nanoparticles to combat infections caused by multiresistant and difficult to treat...
[vc_row][vc_column][vc_column_text] Osteoarthritis is among the leading causes of physical disability with numbers rising. Currently, seven percent of the global population is affected. Patients...
[vc_row][vc_column][vc_column_text].As specialist in antibody search and procurement, Abyntek Biopharma we make the entire process much simpler, supporting the researchers across all phases to find...
[vc_row][vc_column][vc_column_text] On the occasion of International DNA Day, Abyntek Biopharma has released a new CRISPR product range endorsed by the prestigious Broad Institute MIT and...
[vc_row][vc_column][vc_column_text].Artificial intelligence applied to medicine can mean a qualitative leap in adherence to treatment for patients with various pathologies, while improving their...
[vc_row][vc_column][vc_column_text].PharmaBoardroom, a leading British media specialized in the health sector, has published an article in which it highlights VIVEbiotech as one of the ten Spanish...
The healthcare services optimisation startup Panel Health has been selected for the European Reactor programme. Health Venture Lab Reactor is an accelerator programme created by GE Healthcare with...
[vc_row][vc_column][vc_column_text].The Association of Physiotherapists of the Basque Country seeks to be at the forefront of innovation by offering digital rehabilitation software to its...
The independent cooperative from Alava i+Med has presented a three-year investment project endowed with 20 million euros and in which the launch of the Biomedical Institute of Intelligent...
In the spirit to contribute to the excellence in the supply of reagents for research, Abyntek has launched Abyntek Research Reagents, a new range of highest quality bioreagents for cancer research,...
Abyntek strengthens its leadership in the distribution of the highest quality reagents for research, adding to its portfolio a wide variety of primary and secondary antibodies, proteins, ELISA kits...
